Don Dizon, MD on the Experiences of Gay and Transgender Patients With Cancer

Article

Don Dizon, MD, spotlights the daunting experiences lesbian, gay, bisexual, and transgender patients with cancer face, tracing that experience from diagnosis throughout treatment and continuing into symptom management.

In an interview with CancerNetwork®, Don Dizon, MD, FACP, FASCO, director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, emphasizes the experience of lesbian, gay, bisexual, and transgender patients with cancer and negative interactions that can impact their cancer care experience.

Transcript:

What people may not realize, particularly my colleagues, is that any person who identifies as lesbian or gay or bisexual or trans[gender], every single time they meet a new doctor, there’s that moment of anxiety of, ‘Do I need to come out to this person? Are they going to ask me? What are going to be the repercussions if I do?’ Now imagine that someone is being treated for cancer, which is a multidisciplinary treated disease these days. You’re not only meeting an oncologist; you’re meeting nursing staff, infusion staff, navigators, [and] medical assistants, in addition to a medical oncologist, a radiation oncologist, and even a surgeon. All those time points, do you need to come out? It’s really quite daunting. All you need is 1 event where that [patient] was treated with disrespect and it can color the whole experience for that person. And not in good ways.

Recent Videos
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Related Content